Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroFLiPP - Parametric PET of Neuroinflammation in Fatty Liver Disease
NCT06453915Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fludeoxyglucose f 18 in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by University of California, Davis. Primary endpoint: Results of 18F-FDG scans compared with results of DPA-714 scans at 3 months. Started Apr 2025; status: recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06453915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453915.